Home
Resources
Follow portfolio news
...

WuXi Biologics confirms its leadership in sustainable development with another listing in the Dow Jones Sustainability 2024 Index

Published on
13/1/2025
Amended on
23/3/2026
0
minute(s)
Odyssey 2021
WuXi Biologics
For the second year running, WuXi Biologics achieves global recognition for sustainable practices, consolidating its position as a leader in green biologics solutions. The company has designed a world-leading biologics technology platform, offering integrated end-to-end solutions to support organizations in the development and production of biologics, from conception to commercial manufacturing. WuXi Biologics' unique solutions and technology platforms are designed to help its international customers reduce drug development lead times, cut biologics production costs and offer biomanufacturing partners a reliable, high-performance, high-quality global supply network.
By
Charles Pinsolle
Charles Pinsolle
WuXi Biologics confirms its leadership in sustainable development with another listing in the Dow Jones Sustainability 2024 Index
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
Questo articolo è stato tradotto automaticamente. Ci scusiamo per eventuali inesattezze o errori di traduzione.

At the top of the sustainability indexes

WuXi Biologics, a company featured in the Vintage Altaroc Odyssey 2021, has once again been named to the prestigious Dow Jones Sustainability Index (DJSI) for the year 2024. This distinction reflects the company's ongoing efforts in the field of sustainable development and its significant advances in environmental, social and governance (ESG) areas.

Launched in 1999, the DJSI is a global benchmark for investors seeking to integrate sustainable practices into their portfolios. The DJSI World index, in particular, comprises the top 10% of the S&P Global Broad Market Index's top 2,500 companies in terms of long-term sustainability.

Chris Chen, CEO of WuXi Biologics and Chairman of the company's ESG Committee, said: "Being included in the DJSI for the second year running is an honor that rewards our ongoing commitment to sustainability. We continue to push the boundaries of innovation to offer sustainable and responsible solutions to our international partners. We remain committed to promoting responsible practices throughout the value chain."

Exemplary ESG performance

WuXi Biologics has won numerous awards for its achievements in sustainable development. The company has also been named one of the United Nations' 20 Examples of Sustainable Development for 20 Years for its innovative eco-friendly biological solutions.

By pursuing its sustainable initiatives, WuXi Biologics affirms its determination to play a central role in the ecological transformation of the biologics industry, while offering innovative and responsible solutions to patients and partners worldwide.

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
No items found.
Rest of the world
Healthcare
Welcome to Altaroc
To provide you with a tailored experience, we invite you to complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
Your investor profile
Financial intermediary or Professional investor
Financial advisors, wealth management advisors, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced Investor or Altaroc Investor
Private investors who have already invested in Altaroc who have a minimum investment capacity of €100,000.
Private investors who have already invested in Altaroc who have a minimum investment capacity of €250,000.
Inexperienced investor
Individual investors with an investment capacity of less than €100,000.
Individual investors with an investment capacity of less than €250,000.
Institutional investor
Pension funds, retirement funds, asset management firms, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.